The CACHE Study: Coronary Artery Care in HaEmophilia
NCT06706206 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80
Last updated 2026-03-11
Summary
The investigators will use state-of-the-art imaging to look at heart disease in people with haemophilia. Haemophilia is an inherited disorder in which blood does not clot properly because of lack of a key 'glue' blood component (chemicals known as factor VIII or IX). People with haemophilia are 40% less likely to die of heart disease, but it is not known exactly why this is. Understanding heart disease in people with haemophilia is important because better treatments for haemophilia mean that these patients are now living longer, but doctors still don't know if the risk for heart disease in these patients as they age is the same as that for the general population. If these processes are better understand (perhaps less blood clotting is actually protecting the heart from blockage-causing clots), scientists might be able to reduce the risk of heart attacks for everybody.
The UK's first photon-counting detector cardiac CT scanner generates detailed images of the heart and its blood vessels by counting individual X-ray photons. Together with artificial intelligence tools, it is possible to extract a lot of information from these images. As people age, fat is deposited in the vessels which supply blood to the heart which forms plaques. Plaques cause narrowing of the vessels, reducing blood flow to the heart, and can also burst (rupture), leading to a blood clot and heart attack. The new CT scan will show the type and amount of plaques, and quantify the risk of plaque rupture, in people with haemophilia; and the investigators will compare this to people without haemophilia.
Understanding the role of factor VIII/IX in heart attacks will improve management of heart disease in people with haemophilia, and may also lead to new prevention and treatment strategies that benefit heart health for everyone.
Conditions
- Haemophilia
- Cardiovascular Diseases
Interventions
- OTHER
-
Observational trial
Observational clinical trial. Participants will undergo cardiovascular risk assessment (clinical and blood tests) and coronary CT angiogram. These results will be compared to a control population without haemophilia (recruited as part of a different clinical trial).
Sponsors & Collaborators
-
Oxford University Hospitals NHS Trust
lead OTHER
Eligibility
- Min Age
- 45 Years
- Max Age
- 120 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-02-25
- Primary Completion
- 2026-07-31
- Completion
- 2032-01-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
Acquired Hemophilia A and Autoimmunity. Study of Lymphocyte Populations and Myeloid-Derived Suppressor Cells
NCT04805021 ·Status: RECRUITING
-
Treatment of Hemophilia A Patients With FVIII Inhibitors
NCT04023019 ·Status: RECRUITING
-
Study Evaluating Inhibitor Specificity in Hemophilia A
NCT00151385 ·Status: WITHDRAWN ·Phase: PHASE4
-
Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants
NCT03876301 ·Status: COMPLETED
-
Platelet Function in Patients With Hemophilia A
NCT02093065 ·Status: COMPLETED
-
Non Substitutive Strategies to Improve Haemophilia Care in Developing Countries. Experience in Ivory Coast.
NCT03054662 ·Status: COMPLETED ·Phase: NA
-
Inhibitor Development in Patients With Hemophilia A Undergoing Surgery
NCT01571934 ·Status: COMPLETED
-
Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A
NCT02697370 ·Status: COMPLETED ·Phase: PHASE4
-
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
NCT00945906 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A
NCT04131036 ·Status: RECRUITING
-
A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A
NCT01580293 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Hemophilia Inhibitor Previously Untreated Patient Study
NCT01652027 ·Status: COMPLETED
-
Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A
NCT02280265 ·Status: UNKNOWN ·Phase: NA
-
UK - EHL Outcomes Registry
NCT02938156 ·Status: UNKNOWN
-
An Exploration of the Impact of Gene Therapy on the Lives of People With Haemophilia and Their Families
NCT04723680 ·Status: COMPLETED
-
Tissue Factor Pathway Inhibitor (TFPI) and Haemorrhagic Manifestations in Haemophilia A and B Patients
NCT02540187 ·Status: COMPLETED
-
A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A
NCT06297655 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
NCT03695978 ·Status: RECRUITING
-
Inter Individual Variability in Initiation Pathway Activation and Regulation and Phenotypic Heterogeneity in Patients With Haemophilia A and B
NCT03287999 ·Status: UNKNOWN
-
A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.
NCT02246881 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Anticoagulation in a Patient With Severe Hemophilia A
NCT07314983 ·Status: RECRUITING
-
Accessibility of Prophylaxis and On-demand Treatment for Persons With Haemophilia and Other Coagulation Deficiencies
NCT04775888 ·Status: UNKNOWN
-
Personalized Prediction of Tolerance and Immunogenicity in Hemophilia
NCT01626105 ·Status: UNKNOWN
-
A Factor IX Gene Therapy Study (FIX-GT)
NCT03369444 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A
NCT01775618 ·Status: COMPLETED ·Phase: PHASE3